Ciprofloxacin hydrochloride: adverse event reports filed with FDA

3,653

reports as suspect product

0% of all reports · about 162 a year

375

reports, 12 months to June 2026

379 in the 12 months before

94.2%

marked serious by the reporter

89.7% across the class

6.1%

record death among outcomes, as reported

222 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Ciprofloxacin hydrochloride reports recording the termmedian drug in fluoroquinolone antibacterial

1. Vomitingbeing sick16.5%604
2. Drug hypersensitivityan allergic-type reaction to a medicine14.6%533
3. Pneumonialung infection14.5%531
4. Malaisegeneral feeling of being unwell12.9%473
5. Wheezingwheezing12.9%471
6. Dyspnoeashortness of breath12.8%467
7. Painpain, site not specified11.8%430
8. Nauseafeeling sick11.1%407
9. Drug ineffectivethe medicine did not work as expected11%402
10. Off label useused for a purpose or in a way not on the label10.9%400
11. Asthmaasthma10.5%382
12. Oedemaswelling from fluid10.4%379
13. Headachehead pain9.8%359
14. Diarrhoealoose or frequent stools9.7%354
15. Abdominal painstomach or belly pain7.5%274
16. Anxietyanxiety7.4%271
17. Fatiguetiredness7.4%270
18. Rashskin rash7.3%267
19. Arthralgiajoint pain7%257
20. Pyrexiafever6.2%227
21. Dizzinesslight-headedness or unsteadiness6%218
22. Coughcough5.9%214
23. Erythemaskin redness5.8%213
24. Pruritusitching5.5%201
25. Depressionlow mood5.1%188
26. Abdominal pain upperupper stomach pain5.1%186
27. Chest painchest pain4.9%179
28. Drug intolerancethe medicine was not tolerated4.8%176
29. Condition aggravatedthe condition being treated got worse4.6%168
30. Hypersensitivityan allergic-type reaction4.5%166

Top 30 of 926 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 7 drugs in the fluoroquinolone antibacterial class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 88,718 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 16.2% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 3,653 reports.

Drugs most often listed in the same reports

Other products listed in reports where Ciprofloxacin hydrochloride is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the fluoroquinolone antibacterial class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Ciprofloxacin hydrochloride as a suspect or interacting product; reports listing it only as a concomitant medication (2,501) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.